Systemic delivery of human growth hormone or human factor IX in dogs by reintroduced genetically modified autologous bone marrow stromal cells

Human Gene Therapy

Volumn 8, Issue 2, 1997, Pages 137-156

  Hurwitz, David R ^a   Kirchgesser, Michael ^c   Merrill, Wilma ^a   Galanopoulos, Theofanis ^a   McGrath, Claire A ^a   Emami, Shahin ^d   Hansen, Michael ^a   Cherington, Van ^a   Appel, Joseph M ^a   Bizinkauskas, Christine B ^a   Brackmann, Hans Herrmann ^c   Levine, Peter H ^b   Greenberger, Joel S ^e  

^a ALG Company   (United States)

^b Med Center of Central Massachusetts   (United States)

^c UNIVERSITY OF BONN   (Germany)

^d CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^e Ctr de Rech Paris Saint Antoine ^*

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; HUMAN GROWTH HORMONE;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL TRANSPLANTATION; CONTROLLED STUDY; CRYOPRESERVATION; DNA TRANSFECTION; DOG; EXPRESSION VECTOR; GENE TARGETING; GENE THERAPY; GROWTH HORMONE BLOOD LEVEL; HUMAN; ILIAC CREST; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; STROMA CELL;

EID: 16944363593     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1997.8.2-137     Document Type: Article

References (67)

1. AL-HENDY, A., HORTELANO, G., TANNENBAUM, G.S., and CHANG, P.L. (1995). Correction of the growth defect in dwarf mice with nonautologous microencapsulated myoblasts - an alternate approach to somatic gene therapy. Hum. Gene Ther. 6, 165-175.
2. ALFORD, F.P., BAKER, H.W., and BURGER, H.G. (1973). The secretion rate of human growth hormone. I. Daily secretion rates, effect of posture and sleep. J. Clin. Endocrinol. Metab. 37, 515-520.
3. ALTMAN, P.L., and DITTMER, D.S., eds. (1974). Biology Data Book. (Fed. Am. Soc. Exp. Biol., Washington, DC).
4. ANKLESARIA, P., KASE, K., GLOWACKI, J., HOLLAND, C.A., SAKAKEENY, M.A., WRIGHT, J.A., FITZGERALD, T.J., LEE, C.Y., and GREENBERGER, J.S. (1987). Engraftment of a clonal bone marrow stromal cell line in vivo stimulates hematopoietic recovery from total body irradiation. Proc. Natl. Acad. Sci. USA 84, 7681-7685.
5. ANKLESARIA, P., FITZGERALD, T.J., KASE, K., OHARA, A., and GREENBERGER, J.S. (1989). Improved hematopoiesis in anemicS1/S1d mice by splenectomy and therapeutic transplantation of a hematopoietic microenvironment. Blood 74, 1144-1151.
6. BARR, E., and LEIDEN, J.M. (1991). Systemic delivery of recombinant proteins by genetically modified myoblasts [see comments]. Science 254, 1507-1509.
7. BENDER, M.A., GELINAS, R.E., and MILLER, A.D. (1989). A majority of mice show long-term expression of a human beta-globin gene after retrovirus transfer into hematopoietic stem cells. Mol. Cell. Biol. 9, 1426-1434.
8. BRAZOLOT MILLAN, C.L., and CARTER, R.F. (1993). Apparent engraftment of transduced long-term culture adherent cells into the canine bone marrow compartment, following intravenous or direct intra-marrow infusion. Blood 82(Suppl. 1), 428a.
9. BRAZOLOT, MILLAN, C.L., HAWLERY, R.G., and CARTER, R.F. (1994). Expression of canine factor IX by transduced long-term culture adherent cells, and their engraftment in the canine bone marrow compartment following autologous transplantation. Blood 84, 100a.
10. BRETTLER, D.B., and LEVINE, P.H. (1994). Clinical manifestations and therapy of inherited coagulation factor deficiencies. In Hemostasis and Thrombosis. Basic Principles and Clinical Practice, R.W. Colman, J. Hirsh, V.J. Marder, and E.W. Salzman, eds. 3rd ed. pp. 169-183.
11. CHANG, P.L., CAPONE, J.P., and BROWN, G.M. (1990). Autologous fibroblast implantation. Feasibility and potential problems in gene replacement therapy. Mol. Biol Med. 7, 461-470.
12. CHERTKOV, J.L., DRIZE, N.J., GUREVITCH, O.A., and SAMOYLOVA, R.S. (1985). Origins of hemopoietic stromal progenitor cells in chimeras. Exp. Hematol. 13, 1217-1222.
13. CHOWDHURY, J.R., GROSSMAN, M., GUPTA, S., CHOWDHURY, N.R., BAKER, J., JR. and WILSON, J.M. (1991). Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. Science 254, 1802-1805.
14. DAI, Y., ROMAN, M., NAVIAUX, R.K., and VERMA, I.M. (1992). Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. Proc. Natl. Acad. Sci. USA 89, 10892-10895.
15. DHAWAN, J., PAN, L.C., PAVLATH, G.K., TRAVIS, M.A., LANCTOT, A.M., and BLAU, H.M. (1991). Systemic delivery of human growth hormone by injection of genetically engineered myoblasts [see comments]. Science 254, 1509-1512.
16. DING, L.M., SAYLORS, R., and MUNSHI, N.C. (1995). The stromal cells as a vehicle for ex vivo gene therapy. Blood 86(Suppl. 1), 409a.
17. DRIZE, N.J., SURIN, V.L., GAN, O.I., DERYUGINA, E.I., and CHERTKOV, J.L. (1992). Gene therapy model for stromal precursor cells of hematopoietic microenvironment. Leukemia 6, 174S-175S.
18. DWARKI, V.J., BELLONI, P., NIJJAR, T., SMITH, J., COUTO, L., RABIER, M., CLIFT, S., BERNS, A., and COHEN, L.K. (1995). Gene therapy for hemophilia A: Production of therapeutic levels of human factor VIII in vivo in mice. Proc. Natl. Acad. Sci. USA 92, 1023-1027.
19. DZIERZAK, E.A., PAPAYANNOPOULOU, T., and MULLIGAN, R.C. (1988). Lineage-specific expression of a human beta-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells. Nature 331, 35-41.
20. EVANS, W.S., FARIA, A.C., CHRISTIANSEN, E., HO, K.Y., WEISS, J., ROGOL, A.D., JOHNSON, M.L., BLIZZARD, R.M., VELDHUIS, J.D., and THORNER, M.O. (1987). Impact of intensive venous sampling on characterization of pulsatile GH release. Am. J. Physiol. 252, E549-556.
21. FAIRHALL, K.M., CARMIGNAC, D.F., and ROBINSON, I.C. (1992). Growth hormone (GH) binding protein and GH interactions in vivo is the guinea pig. Endocrinology 131, 1963-1969.
22. FENJVES, E.S., GORDON, D.A., PERSHING, L.K., WILLIAMS, D.L., and TAICHMAN, L.B. (1989). Systemic distribution of apolipoprotein E secreted by grafts of epidermal keratinocytes: Implications for epidermal function and gene therapy. Proc. Natl. Acad. Sci. USA 86, 8803-8807.
23. FRIEDMANN, T. (1993). Gene therapy - a new kind of medicine. Trends Biotechnol. 11, 156-159.
24. GERRARD, A.J., HUDSON, D.L., BROWNLEE, G.G., and WATT, F.M. (1993). Towards gene therapy for haemophilia B using primary human keratinocytes. Nature Genet. 3, 180-183.
25. GOLDE, D.W., HOCKING, W.G., QUAN, S.G., SPARKES, R.S., and GALE, R.P. (1980). Origin of human bone marrow fibroblasts. Br. J. Haematol. 44, 183-7.
26. GROSSMAN, M., RAPER, S.E., and WILSON, J.M. (1992). Transplantation of genetically modified autologous hepatocytes into nonhuman primates: feasibility and short-term toxicity. Hum. Gene Ther. 3, 501-510.
27. GROSSMAN, M., RAPER, S.E., KOZARSKY, K., STEIN, E.A., ENGELHARDT, J.F., MULLER, D., LUPIEN, P.J., and WILSON, J.M. (1994). Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolemia [see comments]. Nature Genet. 6, 335-341.
28. HINDMARSH, P.C., MATTHEWS, D.R., BRAIN, C.E., PRINGLE, P.J., DI SILVIO, L., KURTZ, A.B., and BROOK, C.G. (1989). The half-life of exogenous growth hormone after suppression of endogenous growth hormone secretion with somatostatin. Clin. Endocrinol. 30, 443-450.
29. HOLL, R.W., HARTMAN, M.L., VELDHUIS, J.D., TAYLOR, W.M., and THORNER, M.O. (1991). Thirty-second sampling of plasma growth hormone in man: Correlation with sleep stages. J. Clin. Endocrinol. Metab. 72, 854-861.
30. HOLL, R.W., SCHWARZ, U., SCHAUWECKER, P., BENZ, R., VELDHUIS, J.D., and HEINZE, E. (1993). Diurnal variation in the elimination rate of human growth hormone (GH): The half-life of serum GH is prolonged in the evening, and affected by the source of the hormone, as well as by body size and serum estradiol. J. Clin. Endocrinol. Metab. 77, 216-220.
31. HURWITZ, D.R., HODGES, R., DROHAN, W., and SARVER, N. (1987). Optimizing gene expression in BPV-transformed cells: effects of cell type on enhancer/promoter interaction. Nucleic Acids Res. 15, 7137-7153.
32. HUSS, R., SMITH, F.O., MYERSON, D.H., and DEEG, H.J. (1995). Homing and immunogenicity of murine stromal cells transfected with xenogeneic MHC class II genes. Cell Transpl. 4, 483-491.
33. ISHIDA, T., INABA, M., HISHA, H., SUGIURA, K., ADACHI, Y., NAGATA, N., OGAWA, R., GOOD, R.A., and IKEHARA, S. (1994). Requirement of donor-derived stromal cells in the bone marrow for successful allogeneic bone marrow transplantation. Complete prevention of recurrence of autoimmune diseases in MRL/MP-Ipr/Ipr mice by transplantation of bone marrow plus bones (stromal cells) from the same donor. J. Immunol. 152, 3119-3127.
34. KAY, M.A., BALEY, P., ROTHENBERG, S., LELAND, F., FLEMING, L., PONDER, K.P., LIU, T., FINEGOLD, M., DARLINGTON, G., POKORNY, W., and WOO, S.L.C. (1992). Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes. Proc. Natl. Acad. Sci. USA 89, 89-93.
35. KAY, M.A., ROTHENBERG, S., LANDEN, C.N., BELLINGER, D.A., LELAND, F., TOMAN, C., FINEGOLD, M., THOMPSON, A.R., READ, M.S., BRINKHOUS, K.M., and et, a. (1993). In vivo gene therapy of hemophilia B: Sustained partial correction in factor IX-deficient dogs [see comments]. Science 262, 117-119.
36. KEATING, A., SINGER, J.W., KILLEN, P.D., STRIKER, G.E., SALO, A.C., SANDERS, J., THOMAS, E.D., THORNING, D., and FIALKOW, P.J. (1982). Donor origin of the in vitro haematopoietic microenvironment after marrow transplantation in man. Nature 298, 280-283.
37. KEITH, J.C., FERRANTI, T.J., MISRA, B., FREDERICK, T., RUP, B., MCCARTHY, K., FAULKNER, R., BUSH, L., and SCHAUB, R.G. (1995). Evaluation of recombinant human factor IX: Pharmacokinetic studies in the rat and the dog. Thrombos. Haemostas. 73, 101-105.
38. KURACHI, K., and DAVIE, E.W. (1982). Isolation and characterization of a cDNA coding for human factor IX. Proc. Natl. Acad. Sci. USA 79, 6461-6464.
39. LAVER, J., JHANWAR, S.C., O'REILLY, R.J., and CASTRO-MALASPINA, H. (1987). Host origin of the human hematopoietic microenvironment following allogeneic bone marrow transplantation. Blood 70, 1966-1968.
40. LEE, J.H., and KLEIN, H.G. (1995). Cellular gene therapy. Hematol. Oncol. Clin. North Am. 9, 91-113.
41. LEIDEN, J.M. (1995). Gene therapy - Promise, pitfalls, and prognosis. New Engl. J. Med. 333, 871-873.
42. LIM, B., APPERLEY, J.F., ORKIN, S.H., and WILLIAMS, D.A. (1989). Long-term expression of human adenosine deaminase in mice transplanted with retrovirus-infected hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 86, 8892-8896.
43. LOZIER, J.N., THOMPSON, A.R., HU, P.C., READ, M., BRINKHOUS, K.M., HIGH, K.A., and CURIEL, D.T. (1994). Efficient transfection of primary cells in a canine hemophilia-B model using adenovirus polylysine DNA complexes. Hum. Gene Ther. 5, 313-322.
44. LYNCH, C.M., CLOWES, M.M., OSBORNE, W.R., CLOWES, A.W., and MILLER, A.D. (1992). Long-term expression of human adenosine deaminase in vascular smooth muscle cells of rats: A model for gene therapy. Proc. Natl. Acad. Sci. USA 89, 1138-1142.
45. MORGAN, J.R., BARRANDON, Y., GREEN, H., and MULLIGAN, R.C. (1987). Expression of an exogenous growth hormone gene by transplantable human epidermal cells. Science 237, 1476-9.
46. MULLIGAN, R.C. (1993). The basic science of gene therapy. Science 260, 926-932.
47. NOLTA, J.A., HANLEY, M.B., and KOHN, D.B. (1994). Sustained human hematopoiesis in immunodeficient mice by cotransplantation of marrow stroma expressing human interleukin-3: Analysis of gene transduction of long-lived progenitors. Blood 83, 3041-3051.
48. PALMER, T.D., THOMPSON, A.R., and MILLER, A.D. (1989). Production of human factor IX in animals by genetically modified skin fibroblasts: Potential therapy for hemophilia B. Blood 73, 438-445.
49. PALMER, T.D., ROSMAN, G.J., OSBORNE, W.R., and MILLER, A.D. (1991). Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc. Natl. Acad. Sci. USA 88, 1330-1334.
50. PEETERS, S., and FRIESEN, H.G. (1977). A growth hormone binding factor in the serum of pregnant mice. Endocrinology 101, 1164-1183.
51. PEREIRA, R.F., HALFORD, K.W., OHARA, M.D., LEEPER, D.B., SOKOLOV, B.P., POLLARD, M.D., BAGASRA, O., and PROCKOP, D.J. (1995). Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc. Natl. Acad. Sci. USA 92, 4857-4861.
52. PIERSMA, A.H., PLOEMACHER, R.E., and BROCKBANK, K.G. (1983). Transplantation of bone marrow fibroblastoid stromal cells in mice via the intravenous route. Br. J. Haematol. 54, 285-290.
53. PLAUTZ, G., NABEL, E.G., and NABEL, G.J. (1991). Introduction of vascular smooth muscle cells expressing recombinant genes in vivo. Circulation 83, 578-583.
54. RAMESH, N., LAU, S., PALMER, T.D., STORE, R., and OSBORNE, W.R. (1993). High-level human adenosine deaminase expression in dog skin fibroblasts is not sustained following transplantation. Hum. Gene Ther. 4, 3-7.
55. RASKIND, W.H., SINGER, J.W., MORGAN, C.A., and FIALKOW, P.J. (1988). Host origin of marrow stromal cells obtained from marrow transplant recipients and transformed in vitro by simian virus-40. Exp. Hematol. 16, 827-830.
56. SELDEN, R.F., HOWIE, K.B., ROWE, M.E., GOODMAN, H.M., and MOORE, D.D. (1986). Human growth hormone as a reporter gene in regulation studies employing transient gene expression. Mol. Cell. Biol. 6, 3173-3179.
57. SIMMONS, P.J., PRZEPIORKA, D., THOMAS, E.D., and TOROKSTORB, B. (1987). Host origin of marrow stromal cells following allogeneic bone marrow transplantation. Nature 328, 429-32.
58. SMITH, G.H., GALLAHAN, D., ZWIEBEL, J.A., FREEMAN, S.M., BASSIN, R.H., and CALLAHAN, R. (1991). Long-term in vivo expression of genes introduced by retrovirus-mediated transfer into mammary epithelial cells. J. Virol. 65, 6365-6370.
59. ST. LOUIS, D., and VERMA, I.M. (1988). An alternative approach to somatic cell gene therapy. Proc. Natl. Acad. Sci. USA 85, 3150-3154.
60. SYKES, P.J., NEOH, S.H., BRISCO, M.J., HUGHES, E., CONDON, J., and MORLEY, A.A. (1992). Quantitation of targets for PCR by use of limiting dilution. BioTechniques 13, 444-449.
61. THOMPSON, A.R. (1977). Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B. J. Clin. Invest. 59, 900-910.
62. TOLSTOSHEV, P. (1993). Gene therapy, concepts, current trials and future directions. Annu. Rev. Pharmacol. Toxicol. 33, 573-596.
63. VOGT, P.M., THOMPSON, S., ANDREE, C., LIU, P., BREUING, K., HATZIS, D., BROWN, H., MULLIGAN, R.C., and ERIKSSON, E. (1994). Genetically modified keratinocytes transplanted to wounds reconstitute the epidermis. Proc. Natl. Acad. Sci. USA 91, 9307-9311.
64. WILSON, F.D., KONRAD, P.N., GREENBERG, B.R., KLEIN, A.K., and WALLING, P.A. (1978). Cytogenetic studies on bone marrow fibroblasts from a male-female hematopoietic chimera. Evidence that stromal elements in human transplantation recipients are of host type. Transplantation 25, 87-88.
65. WILSON, J.M., BIRINYI, L.K., SALOMON, R.N., LIBBY, P., CALLOW, A.D., and MULLIGAN, R.C. (1989). Implantation of vascular grafts lined with genetically modified endothelial cells. Science 244, 1344-1346.
66. WU, D.-D., and KEATING, A. (1991). Engraftment of donor-derived bone marrow stromal cells. Exp. Hematol. 19, 485 (abstr.).
67. YAO, S.N., and KURACHI, K. (1992). Expression of human factor IX in mice after injection of genetically modified myoblasts. Proc. Natl. Acad. Sci. USA 89, 3357-3361.